Objective: To investigate the association between v-Ki-ras2 Kirsten rat sarcoma viral oncogene homologue (KRAS) gene mutations and levels of human leucocyte antigen (HLA) class I antigen in primary lung tumours and metastatic lymph nodes of patients with non-small cell lung cancer (NSCLC). Methods: Patients with NSCLC undergoing tumour resection were enrolled. KRAS codon 12 mutations were analysed in normal lung and lymph node tissue, primary lung tumours and metastatic lymph nodes using polymerase chain reaction-restriction fragment length polymorphism analysis. HLA class I antigen immunostaining was examined using flow cytometry. Results: A total of 65 patients participated in the study. All normal lung tissues had positive HLA class I antigen immunostaining. The majority of primary lung tumours (56/65) and all of the metastatic lymph nodes (31/31) had downregulated HLA class I antigen immunostaining. There was a positive correlation between downregulated HLA class I antigen in primary tumours and metastatic lymph nodes. There was a negative correlation between KRAS codon 12 mutations and the level of HLA class I antigen in primary and metastatic tumours. Conclusions: KRAS codon 12 mutations appear to be important in the downregulation of HLA class I antigen in NSCLC. Abnormal activation of the oncogenic KRAS pathway might provide a new treatment target for NSCLC.
Introduction
Lung cancer is highly prevalent and is the most common cause of cancer deaths worldwide. 1 The number of lung cancer patients is still increasing, with non-small cell lung cancer (NSCLC) accounting for $85% of cases. 2 Despite advances in surgical and chemotherapeutic interventions, the overall survival rate in patients with NSCLC has remained almost unchanged over the past few decades. [3] [4] [5] The occurrence and development of lung cancer is a complex process involving the accumulation of genetic mutations in tumour cells that confer the malignant phenotype, combined with alterations in the microenvironment that facilitate tumour progression. 6, 7 The immune response plays a critical role in detecting and eliminating cancer cells in a process known as immune surveillance. 8 Escaping from immune surveillance is of such importance in cancer progression that it is considered to be the seventh hallmark of cancer. 9, 10 Although increasing evidence suggests that immune responses might contribute to the control of cancer, the impact of immunotherapies on the clinical management of most cancers is still negligible. 11 Therefore, it is essential to identify the mechanisms for escaping immune surveillance in order to increase the contribution of antitumor immune responses to the therapeutic management of neoplasia.
The human leucocyte antigen (HLA) system is the major histocompatibility complex in humans. HLA class I antigens play key roles in the immune recognition of transformed and virally infected cells by binding to 'non-self' or aberrantly expressed proteins and subsequently presenting the newly formed HLA class I-peptide complex to T lymphocytes. 12 This initiates a series of immune reactions that lead to tumour cell elimination by cytotoxic T cells. 12 Loss or downregulation of HLA class I antigens is frequently observed in NSCLC, 13, 14 which plays a decisive role in allowing the tumour cells to escape the immune system, leading to metastasis. 12, 15 The proto-oncogene rat sarcoma viral oncogene homologue (RAS), which encodes the 21 kDa protein p21, is a member of the RAS family of genes. This family of genes encodes small membrane-associated guanosine triphosphate binding proteins that transmit extracellular signals to regulate cell proliferation and differentiation. [16] [17] [18] Among the RAS gene family, the v-Ki-ras2 Kirsten rat sarcoma viral oncogene homologue (KRAS) gene is mutated in 20-30% of cases of NSCLC and it appears to be a negative prognostic factor for survival in NSCLC globally. The majority of mutations are found at KRAS codon 12. 19, 20 As both mutation of the KRAS gene and downregulation of HLA class I antigens have been shown to be important in the pathogenesis of NSCLC, we hypothesized that KRAS gene mutations might represent one of the main mechanisms of HLA class I antigen dysregulation, thus allowing tumour cells to evade immunosurveillance and facilitating tumour progression in NSCLC. In order to explore the possible inductive effect of KRAS gene mutations on HLA class I antigen downregulation and tumour metastasis, a systematic investigation of KRAS gene mutations using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) analysis was undertaken, and the amount of HLA class I antigens using flow cytometry in both primary and metastatic NSCLC tumours was measured.
Patients and methods Patients
Consecutive patients with primary NSCLC who underwent complete tumour resection at the Department of Thoracic Surgery, Provincial Hospital Affiliated to Shandong University, Jinan, Shandong Province, China between July 2011 and June 2012 were enrolled in the study. The histological type of NSCLC and the type of surgical resection used was recorded for each patient. All patients underwent systematic mediastinal lymph node dissections by X-Y.L. according to the classification of lymph node groups for lung cancer described by the International Union Against Cancer in 2009. 21 Lymph node groups 2, 3, 4, 7, 8 and 9 were dissected on the right side; lymph node groups 4, 5, 6, 7, 8 and 9 were dissected on the left side, based on the lung cancer treatment guidelines of the Ministry of Health, China. Lymph nodes were dissected from all patients included in the study; nodes that were pathologically confirmed to be metastases from the NSCLC primary tumours were collected for subsequent analyses. Patients who underwent incomplete resection, preoperative adjuvant radiotherapy or preoperative adjuvant chemotherapy, and those who had a history of other malignancies were excluded from the study.
All patients provided written informed consent to participate in this study and to donate tissue The protocol was approved by the Human Ethics Review Board of the Provincial Hospital Affiliated to Shandong University.
Flow cytometry
Fresh tissue samples were harvested from the following sites during surgery: (i) normal tissues located >5 cm away from the primary lung tumour; (ii) the primary lung tumour; (iii) lymph nodes. Of the lymph nodes selected for further analysis, one half of each lymph node was prepared for flow cytometry and further PCR-RFLP analysis; the other half was processed for routine histological examination. Single-cell suspensions were prepared from tissue samples for flow cytometry as previously reported. 22 Cells (1 Â 10 6 in 100 ml of 10 mM phosphate-buffered saline [PBS; pH 7.4]) were incubated with 20 ml of fluorescein isothiocyanate-conjugated antihuman HLA-ABC antibody (1 : 100 dilution) or negative control fluorescein isothiocyanate-conjugated immunoglobulin G2a antibody (1 : 100 dilution) (Santa Cruz Biotechnology, Santa Cruz, CA, USA) at 0 C for 30 min. A 700-ml aliquot of 10 mM PBS (pH 7.4) was added to the sample tube and 10000 cells in each tube were analysed using a FACScan TM flow cytometer (Becton Dickinson, San Jose, CA, USA) according to the manufacturer's instructions. The results were scored as positive, reduced or negative immunostaining when the percentage of tumour cells stained for HLA class I antigens was >75%, 25-75% and <25%, respectively. 23 Both reduced and negative scores were collectively classified as HLA class I antigen downregulation.
PCR-RFLP analysis
Fresh tissue samples were harvested from the following sites during surgery: (i) normal tissues located >5 cm away from the primary lung tumour; (ii) the primary lung tumour; (iii) lymph nodes. DNA was extracted from 50 mg of the tissue samples using genomic DNA isolation reagent (Gibco BRL, Life Technologies, Grand Island, NY, USA) according to the manufacturer's protocol. The following synthesized primers (Bio-Synthesis, Lewisville, TX, USA) were used in the PCR reaction: sense, 5 0 -ACTGAATATAAACTTGTGGTAGT TGGACCT-3 0 ; antisense, 5 0 -TCAAAGAA TGGTCCTGGACC-3 0 . 24 PCR was performed with 0.5 ng genomic DNA in a final volume of 25-ml reaction mixture containing 0.2 mmol/l primer, 200 mmol/l deoxyribonucleotide triphosphates, 1.75 mmol/l MgCl 2 and 1 U GoTaq Õ DNA polymerase (all reagents were from Promega, Madison, WI, USA). The cycling programme involved preliminary denaturation at 94 C for 5 min, followed by 25 cycles of denaturation at 94 C for 30 s, annealing at 54 C for 40s and elongation at 72 C for 30 s, followed by a final elongation step at 72 C for 1 min. PCR amplifications were performed in an Applied Biosystems Õ 7500 Real-Time PCR System (Applied Biosystems, Foster City, CA, USA).
Mutations in codon 12 of the KRAS gene were detected using PCR-RFLP analysis and MvaI (Amersham, Little Chalfont, UK) as the restriction enzyme. A 157 base pair (bp) fragment was amplified during the PCR that was then digested by MvaI (CCA/ TGG) at 37 C for 90 min. MvaI (10 U) was applied to 10 ml PCR product in a total volume of 50 ml buffer containing 10 mmol/l Tris-HCl (pH 8.5 at 37 C), 10 mmol/l MgCl 2 , 100 mmol/l KCl and 0.1 mg/ml bovine serum albumin (all reagents were from Promega). The products of the restriction enzyme digestion were analysed by electrophoresis using a 2% agarose gel and Horizon Õ 58 Gel Electrophoresis Apparatus (Gibco BRL, Life Technologies), stained with ethidium bromide and photographed by an ultraviolet transilluminator 2000 (Bio-Rad, Hercules, CA, USA). When codon 12 is normal, it contains two MvaI restriction sites, yielding products of 114, 29 and 14 bp. If codon 12 contains a mutation in either of its first two bases then this results in just one MvaI restriction site, yielding products of 143 and 14 bp.
Statistical analyses
All statistical analyses were performed using the SPSS Õ software package, version 16.0 (SPSS Inc., Chicago, IL, USA) for Windows Õ . The difference between the percentage of tumour cells stained for HLA class I antigen in primary lung tumours and metastatic lymph nodes was analysed using Student's t-test. The correlation between the percentage of tumour cells with negative or reduced immunostaining (i.e. downregulated) for HLA class I antigens in primary lung tumours and metastatic lymph nodes was analysed using Spearman's correlation coefficient Differences between the frequencies of KRAS codon 12 mutations in primary lung tumours categorized according to the level of HLA class I antigen immunostaining were evaluated using 2 -test. Differences between the frequencies of KRAS codon 12 mutations in metastatic lymph nodes categorized according to the level of HLA class I antigen immunostaining were evaluated using 2 -test. Differences between the frequencies of KRAS codon 12 mutations in primary lung tumours and metastatic lymph nodes were evaluated using 2 -test. A P-value < 0.05 was considered statistically significant.
Results
A total of 65 patients with NSCLC were included in the study. Of these, 47 were male and 18 were female, with a mean AE SD age of 52.6 AE 9.6 years (range 33-81 years). The histological types of NSCLC were as follows: 37 (56.9%) adenocarcinoma, 21 (32.3%) squamous cell carcinoma, four (6.2%) large cell carcinoma, two (3.1%) adenosquamous and one (1.5%) atypical carcinoid. The surgical resection methods used were as follows: five (7.7%) pneumonectomy, 53 (81.5%) lobectomy and bilobectomy, and seven (10.8%) segmentectomy or wedge resection. A total of 1365 lymph nodes were dissected in the 65 patients, giving a mean of 21 lymph nodes per patient. A total of 56 (4.1%) lymph nodes were selected for analysis in this current study: only one lymph node was randomly chosen from each of 56 patients, because it was most likely to be considered a metastatic lymph node according to the intraoperative judgement of experienced surgeons. (The lymph nodes in nine of the 65 patients were not selected because in the surgeon's opinion macroscopic findings indicated that there was no metastatic disease.) Of the lymph nodes used in this study, 31 were pathologically confirmed to be metastases from the primary NSCLC tumour; including N1 (n ¼ 19; these were located in the ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and intrapulmonary lymph nodes) and N2 (n ¼ 12; these were located in the ipsilateral mediastinal and/or subcarinal lymph nodes) lymph nodes.
All samples of normal lung tissue were positive for HLA class I antigen immunostaining as demonstrated by flow cytometry (Figure 1a ). The mean AE SD percentage of normal lung cells stained positive for HLA class I antigens was 95.35 AE 3.42%.
Among the 65 primary lung tumours, HLA class I antigen immunostaining was demonstrated to be negative in 11 patients (16.9%), reduced in 45 patients (69.2%) and positive in nine patients (13.8%). The mean AE SD percentage of tumour cells stained for HLA class I antigens in the 65 primary lung tumours was 39.68 AE 12.46% (Figures 1b and 1c) .
Among the 31 lymph node metastases, HLA class I antigen immunostaining was demonstrated to be negative in 22 (71.0%) and reduced in nine (29.0%) (Figures 1d  and 1e ). The mean AE SD percentage of tumour cells stained for HLA class I antigens in the 31 lymph node metastases was 15.38 AE 6.24%, which was significantly lower than that in the 65 primary lesions (Student's t-test; P < 0.05). Further analysis showed that there was a significant positive correlation between downregulated HLA class I antigen immunostaining (i.e. negative and reduced immunostaining) in primary lung tumours and downregulation of HLA class I antigen immunostaining in lymph node metastases (r s ¼ 0.487; P < 0.01).
The presence of mutations in codon 12 of the KRAS gene were investigated using PCR-RFLP analysis of normal lung tissues, primary lung tumours, and normal and metastatic lymph nodes is shown in Figure 2 . There were no KRAS codon 12 mutations detected in normal lung and lymph node tissues. Among the 65 primary lesions, KRAS codon 12 mutations were detected in 14 patients (21.5%) with negative or reduced HLA class I antigen immunostaining. KRAS codon 12 mutations were detected in six out of 11 (54.5%) patients with negative HLA class I antigen immunostaining, eight out of 45 (17.8%) patients with reduced HLA class I antigen immunostaining, and in none of the nine patients with positive HLA class I antigen immunostaining. Further analysis indicated that the frequency of KRAS codon 12 mutations in primary lung tumours with negative HLA class I antigen immunostaining was significantly higher than that in primary lung tumours with reduced HLA class I antigen immunostaining ( 2 -test ¼ 4.56; P < 0.05).
Among the 31 lymph node metastases, KRAS codon 12 mutations were detected in 13 (41.9%). The frequency of KRAS codon 12 mutations in lymph node metastases was significantly higher than that in the primary lung tumours ( 2 -test ¼ 4.32; P < 0.05). Among the 31 lymph node metastases, KRAS codon 12 mutations were detected in 11 out of 22 (50.0%) lymph node metastases with negative HLA class I antigen immunostaining, and in two out of nine (22.2%) lymph node metastases with reduced HLA class I antigen immunostaining. The frequency of KRAS codon 12 mutations in lymph node metastases with negative HLA class I antigen immunostaining was higher than that in lymph node metastases with reduced HLA class I antigen immunostaining, but the difference was not significant.
Discussion
Lung cancer is the leading cause of cancerrelated deaths among men and women worldwide, 1 and NSCLC accounts for $85% of all cases. 2 Despite modern surgical, radiation and chemotherapeutic interventions, the prognosis for patients with NSCLC remains poor, with an overall remission rate of <15%. [25] [26] [27] Human leucocyte antigen, the major histocompatibility complex in humans, is specific to each individual and has hereditary features. HLA class I molecules are highly polymorphic transmembrane glycoproteins composed of two polypeptide chains (heavy chain and light chain). The class I heavy chains are encoded by three genes: HLA-A, HLA-B and HLA-C. 28 HLA class I molecules are important for establishing an immune response by presenting endogenous antigens to T lymphocytes, which initiates a chain of immune reactions that lead to tumour cell elimination by cytotoxic T cells. 12 Altered levels of production of HLA class I antigens is a widespread phenomenon in malignancies and is accompanied by significant inhibition of antitumour T cell function. 12 It represents one of the main mechanisms used by cancer cells to evade immunosurveillance. 12 Downregulated levels of HLA class I antigens were detected in $90% of NSCLC tissue sections. 29 Although various types of HLA class I alterations have been found in NSCLC through different mechanisms, 30, 31 it remains unclear whether activation of oncogenic pathways is associated with the abnormalities of HLA class I antigen expression in tumour progression.
The proto-oncogene RAS is the most frequently mutated oncogene in human cancer. 32 The Ras/rapidly accelerated fibrosarcoma (Raf)/mitogen-activated protein kinase (MAPK) pathway is probably the best characterized signal transduction pathway in cell biology. 33 The function of this pathway is to transduce signals from the extracellular milieu to the cell nucleus where Figure 2 . Detection of v-Ki-ras2 Kirsten rat sarcoma viral oncogene homologue (KRAS) gene mutations in codon 12 in normal lung tissues, primary lung tumours, and normal and metastatic lymph nodes using polymerase chain reaction-restriction fragment length polymorphism analysis. The image shows the products of the restriction enzyme digestion analysed by electrophoresis using a 2% agarose gel. Lanes: M, molecular weight marker; 1 and 2, normal lung tissues; 3, 4 and 5, primary lung tumours; 6, 7 and 8, metastatic lymph nodes; 9 and 10, normal lymph nodes. Single band shown in lanes 1, 5 and 9 is an undigested 157 base pair (bp) KRAS fragment (negative control); single band shown in lanes 2 and 10 is a wild-type 114 bp KRAS fragment; single band shown in lanes 3, 4, 6, 7 and 8 is a mutant-type 143 bp KRAS fragment. specific genes are activated for cell growth, division and differentiation. 34 The Ras/Raf/ MAPK pathway is also involved in cell cycle regulation, wound healing and tissue repair, integrin signalling and cell migration. 35, 36 Finally, the Ras/Raf/MAPK pathway is able to stimulate angiogenesis through changes in expression of genes directly involved in the formation of new blood vessels. 37 Thus, signalling through the Ras/ Raf/MAPK pathway regulates a variety of cellular functions that are important for tumorigenesis. 38 As a consequence, dysregulation of this pathway is a common event in cancer. 39 Of the three RAS genes, KRAS is known to play a key role in various oncogenic pathways. [40] [41] [42] In NSCLC, the KRAS gene is mutated in 20-30% of cases and the majority of mutations are found at KRAS codon 12. 20 The present study used flow cytometry to detect the percentage of tumour cells stained for HLA class I antigens in primary NSCLC tumours and lymph node metastases. The results showed that HLA class I antigens were downregulated in 56 out of 65 (86.1%) primary lung tumours compared with all of the 31 lymph node metastases. The mean percentage of tumour cells stained for HLA class I antigens in the 65 primary lung tumours was significantly higher than in the 31 lymph node metastases. There was a significant positive correlation between downregulated HLA class I antigen immunostaining (i.e. negative and reduced immunostaining) in primary lung tumours and the downregulation of HLA class I antigen immunostaining in lymph node metastases, which suggested that the lack of HLA class I antigens might make it easier for cancer cells to escape immune-mediated destruction leading to the development of lymph node metastases. Based on these current findings, it is possible to infer that the reason why HLA class I antigens were downregulated in lymph node metastases compared with the primary lung tumours was because the metastatic tumours were mainly derived from malignant primary tumour cells that had downregulated HLA class I antigen levels.
In this current study, KRAS codon 12 mutations were detected in 21.5% of primary lung tumours, but none were detected in normal lung and lymph node tissues. Furthermore, the KRAS codon 12 mutations were only detected in primary lung tumours that had downregulated levels of HLA class I antigens; none were detected in the primary lung tumours that had positive levels of HLA class I antigens. In addition, the frequency of KRAS codon 12 mutations was significantly higher in primary lung tumours with negative HLA class I antigen immunostaining compared with primary lung tumours with reduced HLA class I antigen immunostaining, which suggested that there was a negative correlation between KRAS codon 12 mutations and HLA class I antigen levels in NSCLC.
This current study also detected KRAS codon 12 mutations in 41.9% of the lymph node metastases and all of these had downregulated levels of HLA class I antigens. The frequency of KRAS codon 12 mutations was significantly higher in lymph node metastases than in primary lung tumours. This result was consistent with the previous inference that suggested that the reason why HLA class I antigens were downregulated in lymph node metastases compared with the primary lung tumours was because the metastatic tumours were mainly derived from malignant primary tumour cells that had downregulated HLA class I antigen levels. Therefore, it can be further inferred that there is a negative correlation between KRAS codon 12 mutations and HLA class I antigen levels in NSCLC tumours, and that the abnormal activation of the KRAS oncogene is important for the downregulation of HLA class I antigens during tumour progression.
Although further analysis of the frequency of KRAS codon 12 mutations in lymph node metastases demonstrated a higher rate in the lymph node metastases with negative HLA class I antigen immunostaining compared with the lymph node metastases with reduced HLA class I antigen immunostaining (50.0% versus 22.2%, respectively), the difference was not significant.
The immune response plays a critical role in detecting and eliminating cancer cells in a process known as immune surveillance. 43 Mounting evidence suggests that two general strategies are utilized by tumour cells to escape immune surveillance: immunoselection (poorly immunogenic tumour cell variants) and immunosubversion (subversion of the immune system). [44] [45] [46] Immunoselection allows HLA class I-negative variants to avoid immune detection, leading to tumour growth and metastatic colonization. Loss or downregulation of HLA class I antigens on the tumour cell surface limits the clinical outcome of peptide-based cancer vaccines aimed at increasing the specific antitumour activity of cytotoxic T cells. [47] [48] [49] Thus, further understanding of HLA class I defects regarding its tissue specificity and molecular mechanisms might help in the design of appropriate therapeutic strategies in cancer treatment.
The current study has shown the downregulation of HLA class I antigens in both primary and metastatic lesions of NSCLC and the correlation between those changes in HLA class I antigens and the presence of KRAS codon 12 mutations. This suggests a possible inductive effect of KRAS codon 12 mutations on HLA class I antigen regulation in cancer progression. Based on these preliminary findings, mutant KRAS detection might be a novel approach to evaluating the clinical response to autologous vaccination in NSCLC patients. Future research will focus on determining the mechanism by which HLA class I antigen downregulation might be induced by abnormal activation of the oncogenic KRAS pathway with a view to providing novel targets for new immunotherapies that stimulate the antitumour immune responses
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